Market research
SLNO Soleno Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- 27.47
- Analyst target
- 53
- Dividend yield
- Not available
- Beta
- -2.22
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8342033094
- Market cap
- 3B
- P/E ratio
- 27.47
- Analyst target
- 53
- Dividend yield
- Not available
- Beta
- -2.22
About
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SLNO discussion.
5 years, 4 months ago
Soleno Therapeutics, Inc is currently in a long term downtrend where the price is trading 39.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Soleno Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 80.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 35.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Soleno Therapeutics, Inc gets an overall score of 2/5.